Acquisition by Magrath George of 90294 shares of Opus Genetics, at 1.0102 subject to Rule 16b-3
| IRD Stock | 1.11 0.06 5.71% |
About 55% of Opus Genetics,'s shareholders are presently thinking to get in. The analysis of overall sentiment of trading Opus Genetics, stock suggests that some investors are interested at this time. The current market sentiment, together with Opus Genetics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Opus Genetics, stock news signals to limit their universe of possible portfolio assets.
Opus |
Filed transaction by Opus Genetics, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Opus Genetics, Fundamental Analysis
We analyze Opus Genetics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Opus Genetics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Opus Genetics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Opus Genetics, is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Opus Genetics, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Opus Genetics, stock to make a market-neutral strategy. Peer analysis of Opus Genetics, could also be used in its relative valuation, which is a method of valuing Opus Genetics, by comparing valuation metrics with similar companies.
Peers
Opus Genetics, Related Equities
| SPNS | Sapiens International | 0.48 | ||||
| GETY | Getty Images | 0.34 | ||||
| NOTE | FiscalNote Holdings | 2.25 | ||||
| STSFF | SmartStop Self | 10.79 |
Complementary Tools for Opus Stock analysis
When running Opus Genetics,'s price analysis, check to measure Opus Genetics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics, is operating at the current time. Most of Opus Genetics,'s value examination focuses on studying past and present price action to predict the probability of Opus Genetics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics,'s price. Additionally, you may evaluate how the addition of Opus Genetics, to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| CEOs Directory Screen CEOs from public companies around the world |